Acrylamide Exposure and Cancer Risk in Decaffeinated Coffee
Acrylamide Classification (IARC)
- The American Cancer Society notes that acrylamide is classified by the International Agency for Research on Cancer (IARC) as a “probable carcinogen” based primarily on animal‑experiment data. Evidence level: based on animal studies; no human causal inference. 1
Human Epidemiologic Evidence on Acrylamide
The American Cancer Society summarizes that large numbers of epidemiologic studies in humans have found no strong evidence linking dietary acrylamide exposure to an increased risk of cancer. Evidence level: moderate‑to‑high (consistent null findings across many human studies). 1
This lack of association extends to coffee consumption in general, including decaffeinated coffee, according to the same American Cancer Society guideline. Evidence level: moderate‑to‑high (derived from the broader human epidemiology review). 1
Safety and Potential Benefits of Decaffeinated Coffee
| Outcome | Potential Effect of Decaffeinated Coffee | Source |
|---|---|---|
| Overall cancer risk | No increase; considered safe for the general population | Advances in Nutrition (2020) |
| Colorectal cancer | Possible protective effect | Advances in Nutrition (2020) |
| Prostate cancer (aggressive) | Possible protective effect | Advances in Nutrition (2020) |
The Advances in Nutrition review states that decaffeinated coffee can be safely consumed as part of a healthy diet and may confer protective benefits for colorectal and prostate cancers. Evidence level: moderate (observational data supporting modest risk reductions). 3
The same review highlights that decaffeinated coffee retains most phenolic acids and flavonoids, preserving the antioxidant and anti‑inflammatory compounds that underlie many of coffee’s health benefits, making it a reasonable caffeine‑free alternative. Evidence level: moderate (chemical analyses confirming phenolic retention). 3